Amycretin
Also known as: NNC0487-0111, NN9487, NN 9487
Classification
Peptide
Regulatory Status
n/a
Sources
2
Review
n/a
Overview
Amycretin is described as a unimolecular dual agonist combining GLP-1 receptor and amylin receptor activity intended to reduce appetite and body weight. Clinical development is ongoing; it is not an approved medicine.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Interactions & cautions
Drug interactions
other GLP-1 receptor agonists, dual agonists, or amylin analogs — Additive GI adverse effects and overlapping metabolic pathways are expected class risks; no approved combination labeling exists. (high)
These are observational flags for review, not individualized instructions.
Sources
- https://en.wikipedia.org/wiki/Amycretin
- PubMed search: amycretin (opens in a new tab)
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw